Literature DB >> 8870632

Seroepidemiology of HTLV-I in relation to that of HIV-1 in the Gauteng region, South Africa, using dried blood spots on filter papers.

M B Taylor1, S P Parker, H H Crewe-Brown, J McIntyre, W D Cubitt.   

Abstract

The seroprevalence of human T-lymphotropic virus type I (HTLV-I), in relation to that of human immunodeficiency virus type I (HIV-1), was determined in a comparative unlinked anonymous antenatal and neonatal (for indirect measurement of maternal antibodies) serosurvey in the Gauteng region of South Africa, using dried blood spots (DBS) and modified particle agglutination assays. Samples were confirmed to be antibody positive by western blot. A total of 2582 DBS collected during 1993 and 1994 from subjects of African, European and coloured origin were tested. Ten were confirmed as positive for HTLV-I and 128 for HIV-1. No antibodies to HTLV-I or HIV-1 were demonstrated in the 221 women of European and coloured origin who were screened. The HTLV-I seroprevalence rate in subjects of African origin appeared to increase from 0% in 1993 to 0.49% in 1994, while HIV-1 seroprevalence rates of 5.2% and 5.4% were recorded for 1993 and 1994 respectively. No significant differences in HTLV-I and HIV-1 seroprevalence rates were noted for the two areas investigated. These results indicate that HTLV-I should be included in infection control programs, and provide baseline data for monitoring the possible spread of HTLV-I in the heterosexual population in this region.

Entities:  

Keywords:  Acquired Immunodeficiency Syndrome; Africa; Africa South Of The Sahara; Clinical Research; Demographic Factors; Developing Countries; Diseases; English Speaking Africa; Examinations And Diagnoses; Hiv Infections; Hiv Serodiagnosis; Laboratory Examinations And Diagnoses; Measurement; Population; Population Characteristics; Pregnant Women; Prevalence; Research Methodology; Research Report; South Africa; Southern Africa; Viral Diseases

Mesh:

Year:  1996        PMID: 8870632      PMCID: PMC2271693          DOI: 10.1017/s0950268800001527

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  33 in total

1.  Distribution and possible spread of human T-cell leukaemia virus type I in human communities in the northern and eastern Transvaal.

Authors:  M C Botha; M Jones; W A de Klerk; N Yamamoto
Journal:  S Afr Med J       Date:  1985-04-27

2.  HTLV-I associated myelopathy, a new clinical entity.

Authors:  M Osame; K Usuku; S Izumo; N Ijichi; H Amitani; A Igata; M Matsumoto; M Tara
Journal:  Lancet       Date:  1986-05-03       Impact factor: 79.321

3.  Seroprevalence of HTLV-I in Natal/KwaZulu.

Authors:  A I Bhigjee; D Thaler; S Madurai; E Gouws; P L Bill
Journal:  S Afr Med J       Date:  1994-06

4.  Serum antibodies to human T-cell leukaemia virus type I in different ethnic groups and in non-human primates in South Africa.

Authors:  W B Becker; M L Becker; T Homma; H D Brede; R Kurth
Journal:  S Afr Med J       Date:  1985-03-23

5.  Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis.

Authors:  A Gessain; F Barin; J C Vernant; O Gout; L Maurs; A Calender; G de Thé
Journal:  Lancet       Date:  1985-08-24       Impact factor: 79.321

6.  Human T-cell leukemia virus (HTLV) in the United Kingdom.

Authors:  M F Greaves; W Verbi; R Tilley; T A Lister; J Habeshaw; H G Guo; C D Trainor; M Robert-Guroff; W Blattner; M Reitz
Journal:  Int J Cancer       Date:  1984-06-15       Impact factor: 7.396

7.  The human type-C retrovirus, HTLV, in Blacks from the Caribbean region, and relationship to adult T-cell leukemia/lymphoma.

Authors:  W A Blattner; V S Kalyanaraman; M Robert-Guroff; T A Lister; D A Galton; P S Sarin; M H Crawford; D Catovsky; M Greaves; R C Gallo
Journal:  Int J Cancer       Date:  1982-09-15       Impact factor: 7.396

8.  Comparative seroepidemiology of HTLV-I and HTLV-III in the French West Indies and some African countries.

Authors:  G de-Thé; A Gessain; L Gazzolo; M Robert-Guroff; G Najberg; A Calender; M Peti; G Brubaker; A Bensliman; F Fabry
Journal:  Cancer Res       Date:  1985-09       Impact factor: 12.701

9.  Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera.

Authors:  Y Hinuma; K Nagata; M Hanaoka; M Nakai; T Matsumoto; K I Kinoshita; S Shirakawa; I Miyoshi
Journal:  Proc Natl Acad Sci U S A       Date:  1981-10       Impact factor: 11.205

10.  The human T-cell leukemia-lymphoma virus in the southeastern United States.

Authors:  D W Blayney; W A Blattner; M Robert-Guroff; E S Jaffe; R I Fisher; P A Bunn; M G Patton; H R Rarick; R C Gallo
Journal:  JAMA       Date:  1983-08-26       Impact factor: 56.272

View more
  5 in total

Review 1.  The use of the dried blood spot sample in epidemiological studies.

Authors:  S P Parker; W D Cubitt
Journal:  J Clin Pathol       Date:  1999-09       Impact factor: 3.411

2.  Co-infection by human immunodeficiency virus type 1 (HIV-1) and human T cell leukemia virus type 1 (HTLV-1): does immune activation lead to a faster progression to AIDS?

Authors:  Eduardo Samo Gudo; Nilesh B Bhatt; Dulce Ramalho Bila; Celina Monteiro Abreu; Amílcar Tanuri; Wilson Savino; Suse Dayse Silva-Barbosa; Ilesh V Jani
Journal:  BMC Infect Dis       Date:  2009-12-22       Impact factor: 3.090

3.  Epidemiological Aspects and World Distribution of HTLV-1 Infection.

Authors:  Antoine Gessain; Olivier Cassar
Journal:  Front Microbiol       Date:  2012-11-15       Impact factor: 5.640

4.  No significant HTLV seroprevalence in German people who inject drugs.

Authors:  Oliver Hohn; Stephen Norley; Claudia Kücherer; Ali Bazarbachi; Hiba El Hajj; Ulrich Marcus; Ruth Zimmermann; Norbert Bannert
Journal:  PLoS One       Date:  2017-08-22       Impact factor: 3.240

Review 5.  Seroprevalence of HTLV-1 and HTLV-2 amongst mothers and children in Malawi within the context of a systematic review and meta-analysis of HTLV seroprevalence in Africa.

Authors:  James M Fox; Nora Mutalima; Elizabeth Molyneux; Lucy M Carpenter; Graham P Taylor; Martin Bland; Robert Newton; Fabiola Martin
Journal:  Trop Med Int Health       Date:  2016-02-03       Impact factor: 2.622

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.